HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    


Top Stocks Set to Outperform
Over the Next 1 to 3 Months.

Click for your free picks >>

Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive

INCY: Incyte Genomics Inc - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

INCYTE GENOMICS INC (NASD)
INCY 7.54 N/A (N/A%) Vol.  0 N/A ET

Day Low - High N/A - N/A
52wk Low - High 1.96 - 8.32
Avg Volume 3,292,672
Industry MED-BIOMED/GENE
Market Cap 874.18 M
Div - Yield 0.00 - 0.00
PE (forward)
PEG Ratio N/A
Current Year Est. -1.64
EPS Last Year -1.71
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
#1 Strong Buy 26.51%
#2 Buy 16.63%
#3 Hold 7.53%
#4 Sell 2.01%
#5 Strong Sell -0.07%
S&P 500 8.70%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 11/10/2009
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
INCYTE GENOMICS INC INCY PREMIUM
VANDA PHARMACT VNDA PREMIUM
AETERNA ZENT-TS T.AEZ PREMIUM
ONCOLYTICS BIO ONCY PREMIUM
See all MED-BIOMED/GENE Peers

BROKERAGE RECOMMENDATIONS
Current ABR 1.54
ABR (Last Week) 1.54
# of Recs in ABR 13
Average Target Price 9.94
Industry Rank by ABR 49 out of 217
Rank in Industry 72 out of 172
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate INCY?
Buy
Sell
Find out what the Zacks Community
thinks of INCY at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR INCY
Zacks Equity Research: Report for INCY
Nov 10, 2009
Zacks Blog: Incyte Beats Estimates Marginally
Nov 09, 2009
Zacks Blog: Favorable Data from Incyte
Sep 24, 2009
Zacks Blog: Cash Concerns for Incyte
Jul 31, 2009
Zacks Blog: Incyte Reaches Agreement with FDA
Jul 22, 2009
More Zacks Commentary
NEWS
Stock research report available on Incyte (NASDAQ:INCY) from SmarTrend Analytics
Nov 16, 2009
Incyte Up 14.4% Since SmarTrend's Buy Recommendation
Nov 09, 2009
BUYINS.NET: Incyte Corp (INCY) Up After BUYINS.NET Report Predicted Strength After Earnings
Nov 05, 2009
Incyte Reports Third Quarter 2009 Financial Results and Provides Update on Drug Development Programs
Nov 05, 2009
WallStSense.com Offers Detailed Analysis on ISRG, FWLT, INCY, CTRP,GLBL and FULT
Nov 03, 2009
More News
EARNINGS ESTIMATES
  This Quarter
12/2009
Next Quarter
03/2010
This Year
12/2009
Next Year
12/2010
Average Estimate -0.38 -0.34 -1.64 -1.35
Number of Estimates 11 6 11 12
Low Estimates -0.51 -0.39 -1.72 -1.64
High Estimate -0.31 -0.28 -1.58 -0.93
Year Ago EPS -0.50 -0.41 -1.99 -1.64
EPS Growth 24.36% 15.85% 17.82% 17.61%

More Estimates

COMPANY DESCRIPTION
Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of new small molecule drugs for cancer and inflammation. Incyte also has strategic alliances with Lexicon Genetics and Medarex focused on the discovery and development of protein therapeutics or antibodies to treat inflammatory diseases and cancer.

Full Company Report
FINANCIALS
EPS TTM -1.71
Sales 3.92
Net Income -171.83
Price/Earnings N/A
Price/Book N/A
Price/Cash Flow N/A
Price/Sales 262.04


More Financials

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research